Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis (Q84314482)

From Wikidata

Jump to navigation Jump to search

scientific article published on 30 July 2009

Language	Label	Description	Also known as
English	Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis	scientific article published on 30 July 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

S Böttcher

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

S Stilgenbauer

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

R Busch

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

M Brüggemann

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

T Raff

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

C Pott

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

K Fischer

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

G Fingerle-Rowson

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

H Döhner

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

M Hallek

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

M Kneba

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

M Ritgen

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

30 July 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

2007-2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19641522%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.140

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84314482&oldid=2243080120"